A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of Phase 1b of the study is to determine the maximum tolerated dose (MTD) of
oprozomib in combination with melphalan and prednisone (OMP).
The purpose of Phase 2 of the study is to estimate the overall response rate (ORR) and
complete response rate (CRR) of the OMP combination.